| 4.77 0.5 (11.71%) | 09-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.5 |
1-year : | 9.85 |
| Resists | First : | 6.42 |
Second : | 8.43 |
| Pivot price | 5.18  |
|||
| Supports | First : | 3.16 |
Second : | 2.62 |
| MAs | MA(5) : | 4.71 |
MA(20) : | 5.43 |
| MA(100) : | 4.08 |
MA(250) : | 3.97 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.7 |
D(3) : | 6.9 |
| RSI | RSI(14): 47.1 |
|||
| 52-week | High : | 17.95 | Low : | 2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ UPC ] has closed above bottom band by 25.3%. Bollinger Bands are 43.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.27 - 5.31 | 5.31 - 5.34 |
| Low: | 3.92 - 3.95 | 3.95 - 3.98 |
| Close: | 4.71 - 4.77 | 4.77 - 4.83 |
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.
Wed, 02 Sep 2026
Origin Force Intelligence Limited Holds 18.3% Passive Stake in Universe Pharmaceuticals (NASDAQ: UPC) - kalkinemedia.com
Wed, 02 Sep 2026
UPC Stock Pullback Has Traders Watching Key Levels - StocksToTrade
Wed, 02 Sep 2026
UPC Stock Pullback Puts Short-Term Momentum At Risk - timothysykes.com
Wed, 02 Sep 2026
UPC Stock Slides As Momentum Fades From Summer Spike - StocksToTrade
Wed, 02 Sep 2026
Universe Pharmaceuticals Shares Jump 38.64% After Hours - Universe Pharmaceuticals (NASDAQ:UPC) - Benzinga
Tue, 01 Sep 2026
A new 18% owner surfaces at Universe Pharmaceuticals (UPC) - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 6 (K) |
| Shares Short P.Month | 239 (K) |
| EPS | -1.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 99.63 |
| Profit Margin | -11 % |
| Operating Margin | -16.7 % |
| Return on Assets (ttm) | -1.8 % |
| Return on Equity (ttm) | -3.6 % |
| Qtrly Rev. Growth | -1.3 % |
| Gross Profit (p.s.) | 10.25 |
| Sales Per Share | 28.08 |
| EBITDA (p.s.) | -2.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -3.46 |
| PEG Ratio | 0 |
| Price to Book value | 0.04 |
| Price to Sales | 0.16 |
| Price to Cash Flow | -0.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|